Lewy body dementia affects more than one million people in the United States. It has two forms: Dementia with Lewy bodies and ...

Parkinson's disease causes both movement and cognitive deficits, and for a long time both were thought to be caused by the ...

In Parkinson's disease, certain dopamine-producing neurons in the brain die off, disrupting movement | Microbiology ...

In a recent study published in the Proceedings of the National Academy of Sciences, researchers assessed the capability of two small molecules of disintegrating alpha-synuclein fibrils. Parkinson's ...

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein ...

The Food and Drug Administration has granted Fast Track designation to emrusolmin (TEV-56286) for the treatment of multiple system atrophy.

Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to $2.2bn for Arrowhead Pharmaceuticals’ preclinical candidate.

Amsterdam, July 22, 2024 – To date Parkinson's disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker ...

A novel system to control protein aggregation in a model of Parkinson's disease may answer longstanding questions about how the disease begins and spreads, according to a new study. Initial results ...

Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by the aggregation of alpha-synuclein in the brain. Now, scientists have developed a radioligand that facilitates the ...